Aird & Berlis acted for Biomind on the transaction.
Biomind Labs Inc. (formerly Crosswinds Holdings Inc.), in connection with the Reverse Takeover of Crosswinds Holdings, completed a private placement offering of 4,420,647 subscription receipts at a price of $1.40 per subscription receipt for aggregate gross proceeds of $6,188,906.
On completion of the Reverse Takeover, the subscription receipts were exchanged for common shares of the Company.
Biomind Labs Inc. (OTCMKTS:CRSWF) is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions.
The Aird & Berlis’ team comprised of Richard Kimel (Picture), Marek Lorenc, Danny Kharazmi and David Mba (Capital Markets/M&A).
Law Firms: Aird & Berlis LLP;
Clients: Biomind Labs Inc.;